Moscarelli Marco, Terrasini Nora, Nunziata Anna, Punjabi Prakash, Angelini Gianni, Solinas Marco, Buselli Alba, Sarto Paolo Del, Haxhiademi Dorela
GVM Care & Research, Anthea Hospital, Bari, Italy.
Operative Unit of Anesthesiology, G. Pasquinucci Heart Hospital, Fondazione Toscana G. Monasterio, Massa, Italy.
J Cardiothorac Vasc Anesth. 2018 Dec;32(6):2562-2569. doi: 10.1053/j.jvca.2018.01.028. Epub 2018 Jan 31.
Minimally invasive mitral valve repair may be associated with prolonged cardioplegic arrest times and ischemic reperfusion injury. Intravenous (propofol) and volatile (sevoflurane) anesthesia are used routinely during cardiac surgery and are thought to provide cardioprotection; however, the individual contribution of each regimen to cardioprotection is unknown. Therefore, the authors sought to compare the cardioprotective effects of propofol and sevoflurane anesthesia in patients undergoing minimally invasive mitral valve repair.
A single-center single-blind randomized controlled trial.
A specialized regional cardiac surgery center in Italy.
The study enrolled 62 adults undergoing elective isolated minimally invasive mitral valve repair for degenerative disease. Exclusion criteria included secondary mitral regurgitation, previously treated coronary artery disease, diabetes mellitus, chronic renal failure requiring dialysis, atrial fibrillation, and documented allergy to either propofol or sevoflurane.
All patients received video-assisted minimally invasive right minithoracotomy. Patients were randomized to receive propofol or sevoflurane anesthesia in a 1:1 ratio.
Cardiac troponin I release was measured over the first 72 hours postoperatively. Operative, cross-clamp, and total bypass times were similar between groups. Cardiac troponin I release was reduced nonsignificantly in the propofol group (p = 0.62), and peak troponin I release was correlated with cross-clamp time in both groups. There were no differences in terms of intraoperative lactate release and blood pH between groups.
Propofol and sevoflurane anesthesia were associated with similar degrees of myocardial injury, indicating comparable cardioprotection. Myocardial injury was related directly to the duration of cardioplegic arrest.
微创二尖瓣修复术可能与心脏停搏时间延长和缺血再灌注损伤有关。静脉麻醉(丙泊酚)和挥发性麻醉(七氟醚)在心脏手术中常规使用,被认为具有心脏保护作用;然而,每种方案对心脏保护的具体作用尚不清楚。因此,作者试图比较丙泊酚和七氟醚麻醉对接受微创二尖瓣修复术患者的心脏保护作用。
单中心单盲随机对照试验。
意大利一家专门的地区心脏外科中心。
该研究纳入了62例因退行性疾病接受择期孤立性微创二尖瓣修复术的成年人。排除标准包括继发性二尖瓣反流、既往治疗过的冠状动脉疾病、糖尿病、需要透析的慢性肾衰竭、心房颤动以及有记录的对丙泊酚或七氟醚过敏。
所有患者均接受电视辅助微创右胸小切口手术。患者按1:1比例随机接受丙泊酚或七氟醚麻醉。
术后72小时内测量心肌肌钙蛋白I释放量。两组的手术时间、主动脉阻断时间和总体外循环时间相似。丙泊酚组心肌肌钙蛋白I释放量无显著降低(p = 0.62),两组中肌钙蛋白I释放峰值均与主动脉阻断时间相关。两组术中乳酸释放量和血液pH值无差异。
丙泊酚和七氟醚麻醉与相似程度的心肌损伤相关,表明心脏保护作用相当。心肌损伤与心脏停搏持续时间直接相关。